Unleashing the Power of Pharyngeal Electrical Stimulation: A Game-Changer for Post-Stroke Dysphagia
The American Stroke Association (ASA) has made a groundbreaking announcement, recognizing the transformative potential of pharyngeal electrical stimulation (PES) in treating post-stroke dysphagia.
But here's where it gets controversial... While traditional care focuses on monitoring, therapy, and dietary changes, the ASA's new guidelines suggest that PES could be a game-changer for stroke survivors. This innovative therapy targets the neurological components of swallowing coordination, offering a promising solution for those struggling with dysphagia after a stroke.
The ASA's 2026 Guideline for the Early Management of Patients With Acute Ischemic Stroke recommends PES as a "beneficial treatment" to reduce dysphagia's severity and the risk of aspiration. This is particularly significant for patients with severe strokes requiring tracheotomy and mechanical ventilation, as PES can help decrease dysphagia's severity, reduce aspiration risk, and expedite decannulation.
Phagenesis' Phagenyx PES system, a UK-based company's neuromodulation device, is at the forefront of this revolution. It received de novo clearance from the US Food and Drug Administration (FDA) in October 2022 and gained a European CE mark in 2012. The device is the only commercialized PES treatment for patients in the US and EU, offering hope for those affected by dysphagia.
In March 2024, Phagenesis raised $42m in a Series D financing round to accelerate commercialization efforts in the US and deepen market penetration in Europe. This funding will enable the company to expand its reach and make PES more accessible to those in need.
But why is this so significant? Research indicates that 46.6% of stroke survivors experience dysphagia, and up to 50% still struggle with it six months after a stroke. This condition heightens the risk of pneumonia and death, making it a critical barrier to recovery. Historically, there have been "few meaningful therapeutic interventions" to improve patient outcomes, as highlighted by Dr Alex Choi, professor of neurosurgery and neurology at the University of Texas Health Science Center at Houston.
However, the addition of PES to the guidelines signals a shift towards a validated therapeutic option that can be integrated into routine stroke care. This is a significant step forward, offering hope for improved outcomes and quality of life for stroke survivors. As the neuromodulation devices market rapidly advances, PES is poised to play a pivotal role in addressing dysphagia and other conditions, including incontinence, migraine, and depression.
So, what does this mean for the future of stroke care? Will PES become the standard of care for dysphagia? The debate is ongoing, and the ASA's recognition is a crucial step towards making this innovative therapy more widely available. As we continue to explore the potential of neuromodulation, the future of stroke care looks brighter, offering hope for improved outcomes and a better quality of life for those affected by dysphagia.
